相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retinoids, Retinoic Acid Receptors, and Cancer
Xiao-Han Tang et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
Trastuzumab resistance: all roads lead to SRC
Senthil K. Muthuswamy
NATURE MEDICINE (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The biology and treatment of EML4-ALK non-small cell lung cancer
Takaaki Sasaki et al.
EUROPEAN JOURNAL OF CANCER (2010)
Colorectal cancer in review: the role of the EGFR pathway
Muhammad W. Saif
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Drug Developers Unveil Strategies Aimed at Imatinib-Resistant CML
Merrill Goozner
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Imatinib treatment of metastatic GIST: don't stop (believing)
Michael C. Heinrich
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
Massimo Breccia et al.
LEUKEMIA RESEARCH (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Evolution of biomarker qualification at the health authorities
Federico Goodsaid et al.
NATURE BIOTECHNOLOGY (2010)
The HER2 testing conundrum
Malorye Allison
NATURE BIOTECHNOLOGY (2010)
TARGETED THERAPIES Importance of patient selection for EGFR TKIs in lung cancer
Ariel Lopez-Chavez et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Tyrosine-kinase inhibitors-new standard for NSCLC therapy
Nagahiro Saijo
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Nilotinib and dasatinib-new 'magic bullets' for CML?
Massimo Breccia
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
Lisa Hutchinson
Nature Reviews Clinical Oncology (2010)
Emerging companion diagnostics for cancer drugs
Jocelyn August
NATURE REVIEWS DRUG DISCOVERY (2010)
Gene and drug matrix for personalized cancer therapy
Tim Harris
NATURE REVIEWS DRUG DISCOVERY (2010)
Personalized medicine in oncology: the future is now
Richard L. Schilsky
NATURE REVIEWS DRUG DISCOVERY (2010)
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Philip C. De Witt Hamer
NEURO-ONCOLOGY (2010)
Cancer Clinical Trials - A Chronic but Curable Crisis
Robert C. Young
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oncogenic mutations as predictive factors in colorectal cancer
A. Lievre et al.
ONCOGENE (2010)
Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions
Veena Shankaran et al.
ONCOLOGIST (2010)
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses
Dominik Wodarz
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2010)
HDAC inhibitor-based therapies and haematological malignancy
L. Stimson et al.
ANNALS OF ONCOLOGY (2009)
Evolving Treatment of Advanced Colon Cancer
Neil H. Segal et al.
ANNUAL REVIEW OF MEDICINE (2009)
Clinical Practice Patterns and Cost Effectiveness of Human Epidermal Growth Receptor 2 Testing Strategies in Breast Cancer Patients
Kathryn A. Phillips et al.
CANCER (2009)
Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome on HDAC Inhibitor-Induced Apoptosis
Susan Fotheringham et al.
CANCER CELL (2009)
Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective
B. M. Fine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
David O. Azorsa et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
FDA holds court on post hoc data linking KRAS status to drug response
George S. Mack
NATURE BIOTECHNOLOGY (2009)
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
J. Mullenders et al.
ONCOGENE (2009)
Systematic Review of HER2 Breast Cancer Testing
Marta Cuadros et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns et al.
CANCER CELL (2008)
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2008)
Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients
Daniele Santini et al.
EJC SUPPLEMENTS (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
B. D. Badgwell et al.
ANNALS OF ONCOLOGY (2008)
Costs of cancer care in the USA: a descriptive review
K. Robin Yabroff et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Histone deacetylase inhibitors regulate retinoic acid receptor β expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms
Maxy De los Santos et al.
MOLECULAR ENDOCRINOLOGY (2007)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Erlotinib in non-small cell lung cancer treatment: Current status and future development
Cesare Gridelli et al.
ONCOLOGIST (2007)
Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer
Maureen Cronin et al.
CLINICAL CHEMISTRY (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors
Ingo K. Mellinghoff et al.
CLINICAL CANCER RESEARCH (2007)
Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology
Kapila Ratnam et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
G. Valabrega et al.
ANNALS OF ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Imatinib - A review of its use in the management of gastrointestinal stromal tumours
M. Asif A. Siddiqui et al.
DRUGS (2007)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Nickolas Papadopoulos et al.
NATURE BIOTECHNOLOGY (2006)
Mechanisms of disease - Melanoma
Arlo J. Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Identification of serum biomarkers for colon cancer by proteomic analysis
D. G. Ward et al.
BRITISH JOURNAL OF CANCER (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination moth all-trans retinoic acid in patients with acute myeloid leukemia
A Kuendgen et al.
CANCER (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer:: An Oncopaz Cooperative Group Study
J Feliu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
JW Park et al.
CLINICAL CANCER RESEARCH (2004)
Retinoic acid receptors and cancers
DR Soprano et al.
ANNUAL REVIEW OF NUTRITION (2004)
Optimizing treatment of chronic myeloid leukemia: A rational approach
RM Stone
ONCOLOGIST (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Retinoids in cancer therapy and chemoprevention: promise meets resistance
SJ Freemantle et al.
ONCOGENE (2003)
Specific targeted therapy of chronic myelogenous leukemia with imatinib
MWN Deininger et al.
PHARMACOLOGICAL REVIEWS (2003)
Breast and ovarian cancer
R Wooster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyeloicytic leukemia:: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo
DC Zhou et al.
BLOOD (2002)
Molecular targets for breast cancer therapy and prevention
J Bange et al.
NATURE MEDICINE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers
RJ Lin et al.
MOLECULAR CELL (2000)
分享论文
